Turner Syndrome Clinical Trial
Official title:
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Verified date | March 2017 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary objective of this study is to determine whether specific patterns of circulating micro-ribonucleic acids (miRNAs) are associated with aortic aneurysm and dissection in patients with hereditary aortopathy syndromes. The most common of these syndromes is Marfan Syndrome (MFS), but several other recognized aortopathy syndromes are well characterized. The investigators propose the use of a simple blood test, from which miRNA profiles can be measured in individuals with aortopathy syndromes to be compared with miRNAs observed in a control population that has no known predisposition for aortic disease. The investigators hypothesize that microRNA profiles in individuals with Marfan syndrome, and related disorders, will be distinct from those seen in a control group. The investigators predict that up- or down-regulation of certain miRNAs will correlate with the presence and severity of aortic aneurysm, responses to medical therapy, and ultimately could be used to determine when an individual may be at risk of dissection.
Status | Completed |
Enrollment | 20 |
Est. completion date | July 1, 2016 |
Est. primary completion date | July 1, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 60 Years |
Eligibility |
Inclusion Criteria: To be in the study, the participant must meet the following criteria 1. Diagnosis of hereditary aortopathy based upon: - Confirmation of a disease causing mutation in a known aortopathy disorder OR - Confirmation of disease based on published clinical criteria 2. Participants is male or female and greater than 30 days old 3. Participants are able to undergo standard of care cardiac monitoring including an echocardiogram 4. Willing and able to provide written informed consent by parent(s) or guardian(s) after the nature of the study has been explained and prior to any research related procedures 5. Signed HIPPA compliant research authorization Exclusion Criteria: Participant will be excluded from the study for any of the following criteria 1. Diagnosis of a hereditary aortopathy can not be confirmed 2. Existence of an additional comorbid condition- including a co-existing genetic syndrome, heart failure, renal disease, rheumatologic disease, history of malignancy, thyroid disease, recent stroke, other life-limiting illness not related to cardiovascular disease. 3. Extreme prematurity, <28 weeks gestational age |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | University of Colorado Hospital | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Correlation of plasma miRNA with progression of aortic aneurysm | Correlate miRNA patterns with changes in aortic dimension and Z-score longitudinally at yearly time points. | 5 years | |
Primary | Plasma miRNA profiling in individuals with Marfan syndrome | In a cross-sectional analysis, characterize circulating miRNA profiles in individuals with Marfan syndrome and compare to profiles in normal age-matched controls. | 2 years | |
Primary | Plasma miRNA profiling in individuals with aortopathy syndromes | In a cross-sectional analysis, characterize circulating miRNA profiles in individuals with aortopathy syndromes and compare to profiles in normal age-matched controls. | 3 years | |
Secondary | Correlation of plasma miRNA profiles with aortic dimensions | In a cross-sectional analysis correlate miRNA profiles with aortic dimension and Z-score, type of medication used, history of aneurysm and/or dissection, and need for surgical intervention in individuals with MFS. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01734486 -
Growth Response in Girls With Turner Syndrome
|
Phase 4 | |
Completed |
NCT01678261 -
X-chromosome Inactivation, Epigenetics and the Transcriptome
|
N/A | |
Completed |
NCT01419249 -
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
|
Phase 4 | |
Completed |
NCT01518036 -
Use of Somatropin in Turner Syndrome
|
Phase 3 | |
Recruiting |
NCT04948658 -
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
|
||
Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
Completed |
NCT02787486 -
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
|
||
Completed |
NCT00877942 -
Sex Differences in Early Brain Development; Brain Development in Turner Syndrome
|
N/A | |
Completed |
NCT00825617 -
Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy
|
N/A | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
Completed |
NCT01322165 -
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
|
N/A | |
Terminated |
NCT00419107 -
Beta Cell Function in Women With Turner Syndrome
|
N/A | |
Active, not recruiting |
NCT00625001 -
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
|
N/A | |
Completed |
NCT00029159 -
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome
|
Phase 3 | |
Completed |
NCT01518062 -
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
|
Phase 4 | |
Completed |
NCT00471731 -
Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure
|
N/A | |
Completed |
NCT00256126 -
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
|
Phase 4 | |
Completed |
NCT03181230 -
Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome
|